Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response

Background: Cladribine is a highly effective immunotherapy that is applied in two short-term courses over 2 years and reduces relapse rate and disease progression in patients with relapsing multiple sclerosis (MS). Despite the short treatment period, cladribine has a long-lasting effect on disease a...

Descrición completa

Detalles Bibliográficos

Principais autores:	Valerie E. Teschner, Ann-Katrin Fleck, Carolin Walter, Anna-Sophie Schwarze, Melanie Eschborn, Timo Wirth, Olga V. Steinberg, Andreas Schulte-Mecklenbeck, I-Na Lu, Marisol Herrera-Rivero, Claudia Janoschka, Jan D. Lünemann, Nicholas Schwab, Gerd Meyer zu Hörste, Julian Varghese, Catharina C. Gross, Refik Pul, Christoph Kleinschnitz, Simone Mader, Edgar Meinl, Monika Stoll, Heinz Wiendl, Luisa Klotz
Formato:	Artigo
Idioma:	Inglês
Publicado:	SAGE Publishing 2023-12-01
Series:	Therapeutic Advances in Neurological Disorders
Acceso en liña:	https://doi.org/10.1177/17562864231211077
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!